The Delivery of mRNA Vaccines for Therapeutics

被引：41

作者：

Nitika ^{[1
,2
]}

Wei, Jiao ^{[1
,2
]}

Hui, Ai-Min ^{[1
,2
]}

机构：

[1] Fosun Pharma USA Inc, Boston, MA 02421 USA

[2] Shanghai Fosun Pharmaceut Ind Dev Co Ltd, Shanghai 200233, Peoples R China

来源：

LIFE-BASEL | 2022年 / 12卷 / 08期

关键词：

mRNA; vaccines; delivery route; formulations; delivery methods; immunity; RESPIRATORY SYNCYTIAL VIRUS; DENDRITIC CELL VACCINES; LIPID NANOPARTICLES; IMMUNE-RESPONSES; INFLUENZA-VIRUS; PROTECTIVE EFFICACY; CATIONIC LIPIDS; RABIES VACCINE; CANCER-THERAPY; IMMUNOGENICITY;

D O I：

10.3390/life12081254

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

mRNA vaccines have been revolutionary in combating the COVID-19 pandemic in the past two years. They have also become a versatile tool for the prevention of infectious diseases and treatment of cancers. For effective vaccination, mRNA formulation, delivery method and composition of the mRNA carrier play an important role. mRNA vaccines can be delivered using lipid nanoparticles, polymers, peptides or naked mRNA. The vaccine efficacy is influenced by the appropriate delivery materials, formulation methods and selection of a proper administration route. In addition, co-delivery of several mRNAs could also be beneficial and enhance immunity against various variants of an infectious pathogen or several pathogens altogether. Here, we review the recent progress in the delivery methods, modes of delivery and patentable mRNA vaccine technologies.

引用

页数：16

共 160 条

[1] mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J].

A Feldman, Robert ;

Fuhr, Rainard ;

Smolenov, Igor ;

Ribeiro, Amilcar ;

Panther, Lori ;

Watson, Mike ;

Senn, Joseph J. ;

Smith, Mike ;

Almarsson, Orn ;

Pujar, Hari S. ;

Laska, Michael E. ;

Thompson, James ;

Zaks, Tal ;

Ciaramella, Giuseppe .

VACCINE, 2019, 37 (25) :3326-3334

[2] Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial [J].

Alberer, Martin ;

Gnad-Vogt, Ulrike ;

Hong, Henoch Sangjoon ;

Mehr, Keyvan Tadjalli ;

Backert, Linus ;

Finak, Greg ;

Gottardo, Raphael ;

Bica, Mihai Alexandru ;

Garofano, Aurelio ;

Koch, Sven Dominik ;

Fotin-Mleczek, Mariola ;

Hoerr, Ingmar ;

Clemens, Ralf ;

von Sonnenburg, Frank .

LANCET, 2017, 390 (10101) :1511-1520

[3] Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines [J].

Aldosari, Basmah N. ;

Alfagih, Iman M. ;

Almurshedi, Alanood S. .

PHARMACEUTICS, 2021, 13 (02) :1-29

[4] Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial [J].

Aldrich, Cassandra ;

Leroux-Roels, Isabel ;

Huang, Katell Bidet ;

Bica, Mihai Alexandru ;

Loeliger, Edde ;

Schoenborn-Kellenberger, Oliver ;

Walz, Lisa ;

Leroux-Roels, Geert ;

von Sonnenburg, Frank ;

Oostvogels, Lidia .

VACCINE, 2021, 39 (08) :1310-1318

[5] Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression [J].

Ambegia, E ;

Ansell, S ;

Cullis, P ;

Heyes, J ;

Palmer, L ;

MacLachlan, I .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2005, 1669 (02) :155-163

[6] Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation [J].

Anderson, Bart R. ;

Muramatsu, Hiromi ;

Nallagatla, Subba R. ;

Bevilacqua, Philip C. ;

Sansing, Lauren H. ;

Weissman, Drew ;

Kariko, Katalin .

NUCLEIC ACIDS RESEARCH, 2010, 38 (17) :5884-5892

[7] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

[8] Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies [J].

Armbruster, Nicole ;

Jasny, Edith ;

Petsch, Benjamin .

VACCINES, 2019, 7 (04)

[9] Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses [J].

Bahl, Kapil ;

Senn, Joe J. ;

Yuzhakov, Olga ;

Bulychev, Alex ;

Brito, Luis A. ;

Hassett, Kimberly J. ;

Laska, Michael E. ;

Smith, Mike ;

Almarsson, Orn ;

Thompson, James ;

Ribeiro, Amilcar ;

Watson, Mike ;

Zaks, Tal ;

Ciaramella, Giuseppe .

MOLECULAR THERAPY, 2017, 25 (06) :1316-1327

[10] Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates [J].

Bates, John T. ;

Pickens, Jennifer A. ;

Schuster, Jennifer E. ;

Johnson, Monika ;

Tollefson, Sharon J. ;

Williams, John V. ;

Davis, Nancy L. ;

Johnston, Robert E. ;

Schultz-Darken, Nancy ;

Slaughter, James C. ;

Smith-House, Frances ;

Crowe, James E., Jr. .

VACCINE, 2016, 34 (07) :950-956

← 1 2 3 4 5 6 7 8 9 10 →